TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02623387

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided paravertebral block
Description: Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound guided paravertebral block
Description: Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
Study: NCT02969915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care Centers
Description: ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Care Centers
Description: ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
Study: NCT03343678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax given alone and then in combination with BI 836826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836826
Description: Venetoclax given in combination with BI 836826
Study: NCT02238782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib 75mg single dose
Description: 3 capsules of 25 mg given as a single dose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [14C] selumetinib IV solution
Description: single, radiolabeled, IV (infused), microdose (80 μg) of \[14C\] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
Study: NCT01656811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol 90 mcg
Description: 90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levalbuterol 180 mcg
Description: 180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: racemic albuterol 180 mcg
Description: 180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 2 actuations QID
Study: NCT00630708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril
Description: 20 mg per day
Study: NCT03276728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 IV
Description: AMG 986 solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 IV
Description: AMG 986 solution for infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 PO
Description: AMG 986 tablets for oral (PO) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 PO
Description: AMG 986 tablets for oral (PO) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 PO
Description: AMG 986 tablets for oral (PO) administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 986 PO
Description: AMG 986 tablets for oral (PO) administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PO
Description: Matching placebo tablets for oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Matching placebo solution for infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Matching placebo solution for infusion
Study: NCT00286091

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same volume subcutaneous injection
Study: NCT01994746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular Glucagon
Study: NCT02402530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo administered as intravenous infusion.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo administered as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid 62.5 mg
Description: Neridronic acid administered as intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neridronic acid 62.5 mg
Description: Neridronic acid administered as intravenous infusion.
Study: NCT01060904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 0.6-1.2 mg/kg IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: 25 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: 6 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: 375 mg/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bleomycin
Description: 10 units/m2 IV every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: 0.9-1.2 mg/kg IV every 2 weeks
Study: NCT03343340

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early CRRT
Description: Continous Renal Replacement Therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late CRRT
Description: Continous Renal Replacement Therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy
Study: NCT00630708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Losartan
Description: 100 mg per day
Study: NCT03343340

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Therapy
Description: Standard Medical Therapy
Study: NCT04312139

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Baseline and prospective follow-up echocardiography
Study: NCT00630708

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benazepril+Losartan
Description: combination treatment of 10 mg benazepril and 50 mg losartan per day
Study: NCT04516733

Intervention type: OTHER
Group type: OTHER
Intervention: supportive care
Description: visit with supportiv unit and neuropsychologue every 3 months
Study: NCT03704805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship bench intervention
Description: The friendship bench intervention consists of six individual counseling sessions and a peer-led group activity. Individual counseling is based on problem-solving therapy and delivered by lay health workers. During individual counseling, participants will be actively encouraged to identify and tackle problems leading to sub-optimal antiretroviral therapy adherence. In the group activity, participants are taught an income generating skill and have the opportunity to share personal experience with former participants of the intervention.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Standard of Care
Description: Study participants receive information on available routine services for common mental disorders, a nurse-led brief support counseling, assessment for antidepressant medication (fluoxetine) by the clinic nurse, and referral to a psychiatric facility if needed, in addition to the standard of care provided according to national antiretroviral therapy guidelines.
Study: NCT00248105

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Physical Activity Management
Description: Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
Study: NCT04090580

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit).

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Continuous glucose monitoring
Description: Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks (n=18) or 2000 mg metformin (n=18). Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit).
Study: NCT02228824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Very low nicotine content cigarettes
Description: 0.07 mg nicotine delivery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal nicotine content cigarettes
Description: 0.8 mg nicotine delivery
Study: NCT02658838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study: NCT04503512

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: removal of fat pad
Description: Removal removal of fat pad

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: non removal of fat pad
Description: non removal of fat pad
Study: NCT01978600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate 0.5%
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Study: NCT02658838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: full amount low molecular weight heparin
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: half amount low molecular weight heparin
Description: Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study: NCT04312139

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Baseline and prospective follow-up echocardiography

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized Tomography Aortic Valve Calcium Score
Description: Baseline and prospective follow-up CT calcium score of aortic valve

Intervention type: DIAGNOSTIC_TEST
Intervention: Computerized Tomography Aortic Valve Calcium Score
Description: Baseline and prospective follow-up CT calcium score of aortic valve

Intervention type: OTHER
Intervention: Untargeted LC/MS and LC-MS/MS
Description: Serum samples untargeted proteomics and metabolomics

Intervention type: OTHER
Intervention: Untargeted LC/MS and LC-MS/MS
Description: Serum samples untargeted proteomics and metabolomics

Intervention type: OTHER
Intervention: Targeted LC/MS and LC-MS/MS
Description: Serum samples targeted proteomics and metabolomics

Intervention type: OTHER
Intervention: Targeted LC/MS and LC-MS/MS
Description: Serum samples targeted proteomics and metabolomics

Intervention type: DIAGNOSTIC_TEST
Intervention: multiplex ELISA
Description: Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.

Intervention type: DIAGNOSTIC_TEST
Intervention: multiplex ELISA
Description: Implementation of novel multiplex ELISA assay on serum samples of aortic valve stenosis prospective cohort.
Study: NCT06023121

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of levels of an exosome-based liquid biopsy signature
Description: Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature

Intervention type: DIAGNOSTIC_TEST
Intervention: Measurement of levels of an exosome-based liquid biopsy signature
Description: Each participant was enrolled to assess the levels of an exosome-based liquid biopsy signature
Study: NCT01495533

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: uncoated AngioSculpt(R)
Description: Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Drug coated AngioSculpt(R)
Description: Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
Study: NCT02175485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg
Description: Pharmaceutical form:tablet Route of administration: oral
Study: NCT04308655

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Interview
Description: Semi-structured interviews

Intervention type: OTHER
Intervention: Surveys
Description: Validated surveys on pain, fear, anxiety, depression, beliefs
Study: NCT01295944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target Area Under the Curve (AUC) x (Creatinine clearance (CrCl) + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, bevacizumab may be continued at the discretion of the treating physician.
Study: NCT02658838

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: No low molecular weight heparin
Description: Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
Study: NCT01022944

Intervention type: PROCEDURE
Group type: OTHER
Intervention: With chronic middle ear effusion
Description: Children with chronic middle ear effusion having adenoidectomy.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Without chronic middle ear effusion
Description: Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
Study: NCT04140435

Intervention type: DEVICE
Intervention: EUS-guided through-the-needle microbiopsy forceps (Moray)
Description: EUS-TTNB procedure technique. An endosonographer of each institution will perform the EUS procedures. Cysts morphology will be recorded and then punctured by using a 19-gauge EUS-FNA needle. Then the through-the-needle microbiopsy forceps (Moray) will be inserted through the needle into the cystic lumen. Microbiopsies will be obtained from the cyst wall randomly and from mural nodules or septae when observed. The open jaws of the forceps will be pushed onto the cyst wall, closed and pulled back to cause visible tenting. Two bites per pass will be obtained. Then the forceps will be removed and the specimen placed in formalin vials. The procedure will be repeated 2 times, or until 2 visible specimens are obtained. After completion of biopsies, the cyst fluid will be completely aspirated and sent for CEA, amylase, glucose and cytology analyses. If a mural nodule is visualized on EUS, it will be accessed separately by using the 19-gauge needle for EUS-FNA cytology.
Study: NCT03312595

Intervention type: DEVICE
Group type: OTHER
Intervention: Restrata TM Wound Matrix
Description: The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
Study: NCT02320760

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription
Study: NCT00420459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
Study: NCT02884401

Intervention type: DEVICE
Group type: OTHER
Intervention: Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)
Description: A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
Study: NCT03870282

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Extension
Description: The intervention is designed to test if sleep tips delivered by text messages can aid with reaching sleep targets. And if additional motivational text messages can further aide with reaching sleep targets.
Study: NCT03685968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopes
Description: Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopes
Description: Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video laryngoscopes
Description: Patients were randomized into one of the three groups through a computer generated randomization schedule. Patients in group A (N= 75) will be intubated using the GlideScope® AVL, patients in group B (N= 75) will be intubated using the King Vision Channeled VL; patients in group C (N=75) will be intubated using the King Vision Video Laryngoscope with Standard (non-channeled) Blade. Patients will only be tested with one device. All patients will be intubated using a conventional ETT.
Study: NCT00837057

Intervention type: PROCEDURE
Group type: OTHER
Intervention: crrt
Description: early CRRT (35 ml/kg/h)\& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
Study: NCT03993795

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-W
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A19010-W
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-F
Description: A snus product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B19010-F
Description: A snus product
Study: NCT00436839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75mg/m² intravenously (day 1) every 21 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Description: 12mg/m² intravenously every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 10mg orally given daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 10mg orally given daily
Study: NCT00530946

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 2.5mg/Atorvastatin 5mg
Description: Single pill combination, dosed once daily for 8 weeks
Study: NCT03400358

Intervention type: OTHER
Intervention: uterocervical angle
Description: the angle between cervical canal and anterior uterine wall is measured sonographically.